The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

Sildenafil citrate (Generic Viagra) Sildenafil is the best known drug in a class ... which you typically only take 30-60 ...

Hims & Hers Health, Inc. reported record Q3 '24 revenues of over $400 million, beating estimates by nearly $19 million, and guided for up to 90% growth in Q4. The online health and wellness ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025. "We have already confirmed a core supplier ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 32 cents in third-quarter 2024 against the year-ago period’s loss of 4 cents per share. The metric was in line with the ...

Direct-to-consumer telehealth company Hims & Hers is defending its sale of compounded glucagon-like peptide agonists, or GLP-1s, even as shortages of the name brand weight loss medications are waning.

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4. The move comes as patients ...

Hims & Hers will host a conference call to review the third quarter 2024 results on November 4, 2024, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's (NYSE:LLY) recent earnings report. Eli Lilly reported a significant ...